Phase 2 Randomized Trial of Trabectedin + Olaparib vs. Trabectedin in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.
Latest Information Update: 06 Dec 2024
At a glance
- Drugs Olaparib (Primary) ; Trabectedin (Primary)
- Indications Leiomyosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- Acronyms TOMAS2
Most Recent Events
- 04 Dec 2024 Status changed from active, no longer recruiting to completed.
- 24 Oct 2023 Primary endpoint has not been met. (Progression free Survival (PFS)) , according to presented at the 48th European Society for Medical Oncology Congress
- 24 Oct 2023 Results assessing feasibility and preliminary activity data of T+O at a median follow-up of 10.2 months presented at the 48th European Society for Medical Oncology Congress